Free Trial
NASDAQ:ABUS

Arbutus Biopharma Q4 2024 Earnings Report

Arbutus Biopharma logo
$3.13 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$3.15 +0.02 (+0.64%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arbutus Biopharma EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.08
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Arbutus Biopharma Revenue Results

Actual Revenue
$1.57 million
Expected Revenue
$2.20 million
Beat/Miss
Missed by -$628.00 thousand
YoY Revenue Growth
N/A

Arbutus Biopharma Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 27, 2025
Conference Call Time
7:30AM ET

Upcoming Earnings

Arbutus Biopharma's Q2 2025 earnings is scheduled for Thursday, August 7, 2025, with a conference call scheduled on Thursday, July 31, 2025 at 8:45 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Arbutus Biopharma Earnings Headlines

Arbutus Biopharma Corporation (ABUS) - Yahoo Finance
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Arbutus Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arbutus Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arbutus Biopharma and other key companies, straight to your email.

About Arbutus Biopharma

Arbutus Biopharma (NASDAQ:ABUS) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing curative therapies for patients with chronic hepatitis B virus (HBV) infection. Headquartered in Warminster, Pennsylvania, with research and development operations in Vancouver, Canada, Arbutus leverages its proprietary lipid nanoparticle (LNP) delivery platform and RNA interference (RNAi) programs to advance a pipeline of therapies designed to achieve functional cure of HBV.

The company’s lead investigational product, AB-729, is an RNAi therapeutic that targets viral transcripts, aiming to reduce key viral proteins and restore immune control. Arbutus is also developing small-molecule capsid assembly modulators (AB-101 and AB-201) to inhibit viral replication by disrupting the formation of the hepatitis B virus capsid. These programs reflect Arbutus’s integrated approach, combining novel delivery technology with complementary antiviral mechanisms to address multiple stages of the HBV lifecycle.

Since its formation in 2015 through the combination of Tekmira Pharmaceuticals and OnCore Biopharma, Arbutus has built a robust intellectual property portfolio covering LNP formulation and formulation components, RNAi chemistries and HBV-related patents. The company maintains strategic collaborations and licensing agreements to extend its platform capabilities and broaden its reach in antiviral development.

Under the leadership of President and Chief Executive Officer Mark J. F. Myers, Arbutus Biopharma is committed to advancing global efforts against chronic hepatitis B. With a presence in North America and partnerships across Europe and Asia, the company seeks to deliver innovative therapies that could transform the treatment landscape and improve outcomes for millions of patients worldwide.

View Arbutus Biopharma Profile

More Earnings Resources from MarketBeat